Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

NCT04186520 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT04186520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04186520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 18, 2020
Completion date
February 28, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma, chronic lymphocytic leukemia (cll), diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma (mcl), marginal zone lymphoma, non hodgkin lymphoma (nhl), primary mediastinal large b-cell lymphoma (pmbcl)